Results : Intentional factors affecting adherence include patient , caregiver and prescriber beliefs about therapies and the disease itself .
Conclusion : Due to the high level of caregiver involvement in the care of patients with AD , strategies that address caregiver concerns may improve adherence
Background / Aims : Treatment adherence is a major problem in numerous medical conditions , and is a particular challenge in patients with Alzheimer 's disease ( AD ) .
Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
Alzheimer disease ( AD ) has a significant impact on caregivers . Administering and managing medications is one of their many daily tasks . More effective modes of drug administration may benefit patient and caregiver , and may improve compliance . A prospect i ve outcome of the IDEAL ( Investigation of TransDermal Exelon in ALzheimer ’s disease ) trial was to evaluate caregiver preference for rivastigmine patches compared with capsules . The 24-week , r and omized , double-blind , double-dummy , placebo- and active-controlled IDEAL trial investigated once-daily rivastigmine patches vs twice-daily capsules in moderate AD patients . Caregivers rated patch adhesion throughout . The AD Caregiver Preference Question naire ( ADCPQ ) assessed patch vs capsule from caregivers ’ perspective , based on expectations , preferences , and satisfaction with treatment . A total of 1,059 caregivers completed the ADCPQ while their respective patients were on study drug . More than 70 % of caregivers preferred the patch to capsules overall . The patch was preferred to capsules with respect to ease of use ( p < 0.0001 ) and ease of following the schedule ( p < 0.0001 ) . Caregivers indicated greater satisfaction overall ( p < 0.0001 ) and less interference with daily life ( p < 0.01 ) with the patch vs capsules . The preference sub study of the IDEAL trial demonstrated that caregivers of AD patients preferred patches to capsules for drug delivery . Preference for the patch may indicate reduced caregiver stress , substantiated by greater satisfaction and less interference with daily life . These benefits may lead to improved compliance
Results : Intentional factors affecting adherence include patient , caregiver and prescriber beliefs about therapies and the disease itself .
Conclusion : Due to the high level of caregiver involvement in the care of patients with AD , strategies that address caregiver concerns may improve adherence
Background / Aims : Treatment adherence is a major problem in numerous medical conditions , and is a particular challenge in patients with Alzheimer 's disease ( AD ) .